On August 1st, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) plans to sell 26.8380% of the equity of Yingkou Yingshixin Chemical Technology Co., Ltd. (referred to as "Yingkou Chemical") held by its wholly-owned subsidiary Shandong Sinobioway Biomedicine Co., Ltd. (referred to as "Sinobioway") through public listing on the Shandong Property Rights Trading Center in order to further optimize resource allocation, improve asset quality, and enhance operational efficiency. The transfer price of this transaction shall not be lower than the appraisal value of the assets evaluated by the asset appraisal agency on the basis of the evaluation report. As the equity transfer of the joint-stock company is intended to be conducted through public listing, the final transaction price will be determined according to the market rules of property rights trading and other related regulations. Upon completion of this transaction, the company will no longer hold equity in Yingkou Chemical.
The subject of this transaction is the 26.8380% equity of Yingkou Chemical held by Sinobioway, and the appraisal value of the total equity of Yingkou Chemical shareholders is used as the pricing benchmark. The company's 26.8380% equity in Yingkou Chemical will be publicly listed for transfer at a price of RMB 98.0468 million on the Shandong Property Rights Trading Center.
